Yazar "Cengiz, Mustafa" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Predictive value of plasma zonulin levels during early gestational weeks in gestational diabetes mellitus
    (2024) Cengiz, Celal; Aktün Tamer, Lebriz Hale; Ülker, Volkan; Cengiz, Mustafa; Özdemir, İsa Aykut
    Objective: This study aimed to determine the impact and predictive utility of serum zonulin levels measured between 11-14 weeks of gestation and 75-g oral glucose tolerance test (OGTT) testing between 24-28 weeks of gestation in predicting patients diagnosed with gestational diabetes mellitus (GDM). Methods: The study included 209 pregnant women at 11-14 weeks of gestation. Among the pregnant women who presented to the Obstetrics and Gynecology Outpatient Department of İstanbul Medipol Mega Hospital, those who could not be reached due to the covid pandemic (69), aborted (4), diagnosed with chromosomal abnormalities in the fetus (3), and those who withdrew from the study (4) were excluded from the study. The study group included 48 pregnant women diagnosed with GDM at 24-28 weeks of gestation. On the other hand, the control group was formed by randomly selecting 40 pregnant women from 81 pregnant women who were not diagnosed with GDM due to the lack of a kit using a computer-based program. GDM was diagnosed using an OGTT performed between 24 and 28 weeks of gestation according to the International Association of Diabetes and Pregnancy Study Groups criteria. Plasma zonulin levels were measured using enzyme-linked immunosorbent assay. Results: When zonulin (ng/mL) and body mass index (BMI) (kg/m2) values were compared between the study and control groups, a significant correlation was found between zonulin (35.77±8.79 (ng/mL), 29.76±6.96 (ng/mL), p=0.01) and BMI (kg/m2) (26.02±2.39, 24.78±2.7 (kg/m2), p=0.032). In addition, a correlation analysis showed a significant positive correlation between plasma zonulin level and first-hour OGTT. Conclusion: The findings of our research indicate that zonulin has the potential to function as a non-invasive biomarker of GDM development. More extensive research is required on this topic.
  • Küçük Resim
    Öğe
    The importance of serum biglycan levels as a fibrosis marker in patients with chronic hepatitis B
    (Wiley, 2017) Çiftçiler, Rafiye; Özenirler, Seren; Atak Yücel, Ayşegül; Cengiz, Mustafa; Erkan, Gülbanu; Büyükdemirci, Erkan; Sönmez, Cemile; Yılmaz Esendağlı, Güldal
    BackgroundLiver biopsy is recommended in the majority of patients with chronic viral hepatitis for fibrosis evaluation. Because of the potential risks of liver biopsy, many studies related to non-invasive biomarkers of hepatic fibrosis have been performed. We aimed to assess the diagnostic value of serum biglycan as a non-invasive fibrosis marker in chronic hepatitis B patients. MethodsThis study included 120 patients with biopsy-proven hepatitis B patients and 60 healthy controls. Fibrosis stage and necroinflammatory activity were assessed in liver biopsy specimens. Biglycan level was measured using an ELISA assay. ResultsSerum biglycan levels of chronic hepatitis B patients were found to be significantly higher than those of healthy controls (337.3363.0pg/mL vs 189.1 +/- 61.9pg/mL, respectively, P<.001). There was a statistically significant positive correlation between serum biglycan level and fibrosis stage (P=.004; r=.213). Besides, a statistically significant positive correlation was found between serum biglycan level and necroinflammatory activity (P<.001; r=.271). The AUROC of BGN levels was 0.702 for fibrosis stage, differentiating patients from healthy controls with statistical significance (P<.001). The AUROC of BGN levels was 0.632 for necroinflammatory activity score, differentiating patients from healthy controls with statistical significance (P=.004). ConclusionsSerum biglycan might be used as a non-invasive marker of liver fibrosis. Further studies are needed to evaluate the usefulness of this marker.